NASDAQ:BEAM - Beam Therapeutics Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
About
FAQ

Consensus Rating: Buy
Consensus Price Target: $94.17
Forecasted Upside: 9.51 %
Number of Analysts: 8
Breakdown:
0 Sell Ratings
4 Hold Ratings
4 Buy Ratings
0 Strong Buy Ratings

^$85.99 As of 06/22/2021 01:00 AM ET

▲ +0.07 (0.08%)

1 month | 3 months | 12 months

Get New Beam Therapeutics Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for BEAM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BEAM

^$94.17

▲ +9.51% Upside Potential

This price target is based on 8 analysts offering 12 month price targets for Beam Therapeutics in the last 3 months. The average price target is $94.17, with a high forecast of $145.00 and a low forecast of $33.00. The average price target represents a 9.51% upside from the last price of $85.99.

Current Consensus is Buy

The current consensus among 8 polled investment analysts is to buy stock in Beam Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations Description Skip Past Price Target Consensus Chart

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

12/30/2019

0 strong buy ratings
2 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

3/29/2020

0 strong buy ratings
2 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

6/27/2020

0 strong buy ratings
3 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

9/25/2020

0 strong buy ratings
3 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

12/24/2020

0 strong buy ratings
3 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

3/24/2021

0 strong buy ratings
4 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

5/23/2021

0 strong buy ratings
4 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

6/22/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
5/11/2021	Redburn Partners	Initiated Coverage	Buy		High
5/3/2021	Royal Bank of Canada	Initiated Coverage	Sector Perform	$85.00	High
3/8/2021	Barclays	Reiterated Rating	Overweight ➝ Equal Weight	$47.00 ➝ $90.00	Low
3/1/2021	Barclays	Downgrade	Overweight ➝ Equal Weight	$47.00 ➝ $90.00	Low
2/25/2021	Wedbush	Boost Price Target		$42.00 ➝ $112.00	High
2/16/2021	Wells Fargo & Company	Initiated Coverage	Overweight	$145.00	Low
1/29/2021	JPMorgan Chase & Co.	Downgrade	Overweight ➝ Neutral	$38.00 ➝ $100.00	Low
1/5/2021	Stifel Nicolaus	Initiated Coverage	Hold		N/A
10/16/2020	Wedbush	Reiterated Rating	Outperform	$40.00	N/A
8/12/2020	William Blair	Initiated Coverage	Buy		N/A
8/5/2020	William Blair	Reiterated Rating	Outperform	$33.00	Medium
8/5/2020	William Blair	Initiated Coverage	Outperform	$33.00	N/A
5/13/2020	Wedbush	Reiterated Rating	Outperform	$32.00	N/A
3/2/2020	Wedbush	Reiterated Rating	Outperform		High
3/2/2020	JPMorgan Chase & Co.	Initiated Coverage	Overweight	$31.00	N/A
3/2/2020	Wedbush	Initiated Coverage	Outperform ➝ Outperform	$32.00 ➝ $32.00	N/A
3/2/2020	Jefferies Financial Group	Initiated Coverage	Buy	$32.00	N/A
3/2/2020	Barclays	Initiated Coverage	Overweight	$32.00	N/A

(Data available from 6/23/2016 forward)

Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia. It also develops therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1a; and therapies for ocular and central nervous system disorders. The company has a strategic alliance with Boston Children's Hospital; a research and clinical collaboration agreement with Magenta Therapeutics, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. Beam Therapeutics Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $85.99

$83.52

$86.90

50 Day Range

MA: $77.52

$64.12

$91.96

52 Week Range

Now: $85.99

$18.76

$126.90

Volume

505,053 shs

Average Volume

958,329 shs

Market Capitalization

$5.38 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.01

Frequently Asked Questions

What sell-side analysts currently cover shares of Beam Therapeutics?

The following Wall Street sell-side analysts have issued research reports on Beam Therapeutics in the last year: Barclays PLC, JPMorgan Chase & Co., Redburn Partners, Royal Bank of Canada, Stifel Nicolaus, Wedbush, Wells Fargo & Company, William Blair, and Zacks Investment Research.
View the latest analyst ratings for BEAM.

What is the current price target for Beam Therapeutics?

6 Wall Street analysts have set twelve-month price targets for Beam Therapeutics in the last year. Their average twelve-month price target is $94.17, suggesting a possible upside of 9.5%. Wells Fargo & Company has the highest price target set, predicting BEAM will reach $145.00 in the next twelve months. William Blair has the lowest price target set, forecasting a price of $33.00 for Beam Therapeutics in the next year.
View the latest price targets for BEAM.

What is the current consensus analyst rating for Beam Therapeutics?

Beam Therapeutics currently has 4 hold ratings and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe BEAM will outperform the market and that investors should add to their positions of Beam Therapeutics.
View the latest ratings for BEAM.

What other companies compete with Beam Therapeutics?

Other companies that are similar to Beam Therapeutics include Novozymes A/S, Bio-Techne, argenx, Novavax, Repligen, QIAGEN, CRISPR Therapeutics, Neurocrine Biosciences, Denali Therapeutics, Fate Therapeutics, Acceleron Pharma, Exelixis, Vir Biotechnology, Halozyme Therapeutics and Recursion Pharmaceuticals.

How do I contact Beam Therapeutics' investor relations team?

Beam Therapeutics' physical mailing address is 26 LANDSDOWNE STREET, CAMBRIDGE MA, 02139. The company's listed phone number is 857-327-8775 and its investor relations email address is [email protected] The official website for Beam Therapeutics is www.beamtx.com.